Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) will
announce its first quarter 2016 financial and operating results after
market close on Monday, May 9, 2016. The Company will host a conference
call and webcast to discuss these results on Tuesday, May 10, 2016 at
8:30 a.m. Eastern Time.
Participants may access the live webcast via the Company's website at www.aezsinc.com,
or by telephone using the following number: 201-689-8029, Confirmation
#13635224. A replay of the webcast will also be available on the
Company’s website for a period of 30 days.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel treatments in oncology,
endocrinology and women’s health. We are engaged in drug development
activities and in the promotion of products for others. We are now
conducting Phase 3 studies of two internally developed compounds. The
focus of our business development efforts is the acquisition of licenses
to products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in territories where such out-licensing would
enable us to ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005255/en/
Copyright Business Wire 2016